Chlamydophila pneumoniae (original) (raw)
Related papers
Expert Opinion on Therapeutic Patents, 2008
Background : Chlamydophila pneumoniae infections are a common cause of acute respiratory diseases, including upper respiratory tract infections and pneumonia. Over the past few years, C. pneumoniae infections have been strongly related to atherosclerotic cardiovascular diseases. Objective : The aim of this review is to offer an update and overview of recent advances in the diagnosis, prevention and treatment of these infections. Methods : Diagnostic systems have improved but further progress is required to allow a reliable diagnosis to be made. This is especially true for atherosclerotic diseases, for which standard criteria need to be established. Results/conclusion : Polymerase chain reaction and serological methods need to be standardized and made better to improve the diagnosis of C. pneumoniae infections. It seems to be crucial to obtain new and more selective antigens associated with persistent infections to explain the participation of C. pneumoniae in coronary artery disease.
Acute Respiratory Infection Due to Chlamydia pneumoniae: Current Status of Diagnostic Methods
Clinical Infectious Diseases, 2007
Reliable diagnosis of respiratory infection due to Chlamydia pneumoniae and investigation of its role in chronic diseases remain difficult because of the absence of well-standardized and commercially available diagnostic tests. In 2001, the US Centers for Disease Control and Prevention published recommendations for standardizing the diagnostic approach. In this review, we discuss the current state of knowledge of C. pneumoniae-associated respiratory infections in the context of epidemiological studies published during the past 5 years, with particular emphasis on the diagnostic strategies used and their impact on results. The single most likely factor underlying wide variations in data is the significant interstudy variation of the choice of diagnostic methods and criteria used. Adoption of a more unified approach, both for choices of diagnostic methods and for validation of new molecular assays, is long overdue and will be critically important for development of a standardized test for clinical laboratories.
Serological studies on Chlamydia pneumoniae infections
2007
Chlamydia pneumoniae is a common, widespread pathogen that causes acute and chronic infections. Serological diagnosis of C. pneumoniae infection is primarily based on the microimmunofluorescence (MIF) method, but only a fourfold IgG antibody increase between paired sera and the presence of IgM antibodies have generally been accepted as markers of acute infection. At the present, no commonly accepted, reliable serological or other methods for the diagnosis of chronic C. pneumoniae infection exist. We evaluated C. pneumoniae specific serological tests in different populations, followed the kinetics of C. pneumoniae antibodies in multiple sera obtained from the same individuals, compared anti-human IgA FITC conjugates in MIF test and evaluated C. pneumoniae specific antibody tests before and after coronary events in case-control pairs matched for the time point of serum sampling, place of residence, and treatment. We showed that reinfection or reactivation is needed for the persistence of elevated IgG and IgA antibody levels. In chronic infections and upon reactivation, chronic processes may be better diagnosable based on IgA persistence than IgG levels because of the rapid disappearance of IgA levels after seroconversions. The cycle of reinfection and reactivation seems to be faster than previously thought in crowded conditions, such as in military service, since we recorded several antibody changes between the arrival and departure sera of military recruits during 6-month service. The presence of antibodies does not provide protection from reinfection. Commercial anti-human IgA conjugates act differently in MIF tests, and there is marked variation in their ability to detect IgA antibodies. The EIA test used here overestimated the prevalence and persistence of IgA antibodies when compared to MIF. The best compability between MIF and EIA antibody levels was seen in the participants with high titers. Only high IgA MIF titers to C. pneumoniae at the baseline predicted future coronary events. In the present study, seroconversions both in the participants who developed a coronary event and in the controls were detected by MIF and EIA, but mostly in different persons. Seroconversion suggesting reinfection or reactivation of persistent infection may have a role in accelerating chronic processes, because the participants with MIF seroconversion between consecutive sera had a slightly higher risk for coronary events than the controls. EIA seroconversions were more common in the controls than in the cases before the coronary event. The difference in the kinetics of EIA and MIF antibodies warrants future research and supports the use of the MIF method as a golden standard in the measurement of C. pneumoniae IgG and IgA antibody levels and seroconversions. In their diagnostic practice, laboratories should use, compare, and validate more C. pneumoniae IgA antibody tests in addition to IgG tests. Unspecific findings in C. pneumoniae EIA tests require re-estimation and a new way to interpret the results. Chlamydia experts should speak for MIF and rethink the meaning of IgA antibodies and recommendations in the diagnosis of C. pneumoniae infections.
Epidemiology of Chlamydia pneumoniae
Clinical Microbiology and Infection, 1998
Chlamydia pneumoniae is the most commonly occurring intracellular bacterial pathogen. It is frequently involved in respiratory tract infections and to a lesser degree in extrapulmonary diseases. According to seroepidemiologic surveys, C. pneumoniae infection seems to be both endemic and epidemic. Such studies indicate that C. pneumoniae infection is widespread, with frequent reinfection during a lifetime. In Western countries the highest rate of new infections occurs between the ages of 5 and 15. The antibody prevalence worldwide is higher in adult males than in females. Currently available data suggest that C. pneumoniae is primarily transmitted from human to human without any animal reservoir. Transmission seems to be inefficient, although household outbreaks with high transmission rates are reported. Most reports rank C. pneumoniae among the three most common etiologic agents of community-acquired pneumonia, with an incidence ranging from 6% to 25%, and generally presenting a mild and, in some cases, self-limiting clinical course.
Chlamydophila pneumoniae diagnostics: importance of methodology in relation to timing of sampling
Clinical Microbiology and Infection, 2009
The diagnostic impact of PCR-based detection was compared to single-serum IgM antibody measurement and IgG antibody seroconversion during an outbreak of Chlamydophila pneumoniae in a military community. Nasopharyngeal swabs for PCR-based detection, and serum, were obtained from 127 conscripts during the outbreak. Serum, drawn many months before the outbreak, provided the baseline antibody status. C. pneumoniae IgM and IgG antibodies were assayed using microimmunofluorescence (MIF), enzyme immunoassay (EIA) and recombinant ELISA (rELISA). Two reference standard tests were applied: (i) C. pneumoniae PCR; and (ii) assay of C. pneumoniae IgM antibodies, defined as positive if ‡2 IgM antibody assays (i.e. rELISA with MIF and/or EIA) were positive. In 33 subjects, of whom two tested negative according to IgM antibody assays and IgG seroconversion, C. pneumoniae DNA was detected by PCR. The sensitivities were 79%, 85%, 88% and 68%, respectively, and the specificities were 86%, 84%, 78% and 93%, respectively, for MIF IgM, EIA IgM, rELISA IgM and PCR. In two subjects, acute infection was diagnosed on the basis of IgG antibody seroconversion alone. The sensitivity of PCR detection was lower than that of any IgM antibody assay. This may be explained by the late sampling, or clearance of the organism following antibiotic treatment. The results of assay evaluation studies are affected not only by the choice of reference standard tests, but also by the timing of sampling for the different test principles used. On the basis of these findings, a combination of nasopharyngeal swabbing for PCR detection and specific single-serum IgM measurement is recommended in cases of acute respiratory C. pneumoniae infection.
Comparison of Five Serologic Tests for Diagnosis of Acute Infections by Chlamydia pneumoniae
Clinical and Vaccine Immunology, 2000
Serology is often used to diagnose acute infections by Chlamydia pneumoniae. In this study paired sera from patients with acute respiratory tract infection during an epidemic of C. pneumoniae infections were examined by five different antibody tests. These tests were the complement fixation (CF) test, the microimmunofluorescence (MIF) test, a recombinant enzyme immunoassay (rEIA) (Medac) based on a recombinant lipopolysaccharide of chlamydia and measuring antibodies to a common chlamydial antigen, and two tests that utilize preparations of C. pneumoniae organisms, the SeroCp-EIA (Savyon) (with preserved lipopolysaccharide) and the LOY-EIA (Labsystems) (without this antigen). Both of the last two tests should measure specific antibodies to C. pneumoniae, although cross-reacting antibodies may also be detected by the SeroCp-EIA. Acute infection of C. pneumoniae was serologically confirmed in 44% of the cases by at least two different tests. Using an expanded "gold standard," i.e., the presence of significant reactions in at least two tests, the sensitivity of the CF test was 69%, that of the MIF test was 88%, that of the rEIA was 89%, that of the LOY-EIA was 96%, and that of the SeroCp-EIA was 92%. Specificity was high for all methods, but adjustments of diagnostic criteria were made to several of the tests. The basis for these adjustments and supportive data are presented. Infections of C. pneumoniae were detected in patients from 8 to 83 years of age. Two peaks in the incidence of such infections were observed: one among young teenagers and a second in adults 30 to 45 years of age, corresponding to parents of young teenagers. The tests were equally sensitive in different age groups. Reinfections seemed to be rare.
Current Medical Issues, 2020
Introduction: Lower respiratory tract infections (LRTIs) continue to be a major health problem in children. Increasingly “atypical” agents such as Chlamydophila pneumoniae are being recognized as a significant cause of LRTI. The current study evaluated serological and molecular methods in detection of LRTI due to C. pneumoniae in young children. Materials and Methods: Serum and nasopharyngeal aspirate (NPA) were collected from 53 treatment-naïve children (6 months–6 years) with LRTI. Immunoglobulin M (IgM) and IgG antibodies to C. pneumoniae were detected in serum by enzyme-linked immunosorbent assay (ELISA) and microimmunofluorescence (MIF) test. Nonnested polymerase chain reaction (PCR) to detect a 183-bp fragment of the 60-kDa outer membrane protein 2 of C. pneumoniae was performed on DNA extracted from the NPA samples. Results: Of the 53 children tested, 14 (26.4%) children were diagnosed to have acute C. pneumoniae infection according to CDC guidelines. When compared with IgM M...
PubMed, 2008
Background: Chlamydia pneumoniae causes a variety of respiratory infections and is involved in cardiovascular diseases. Diagnosis of C. pneumoniae infection currently relies on antibody detection by microimmunofluorescence (MIF), which has limited use, and is the retrospective diagnosis for acute infection. Objective: Find an effective early diagnosis of acute upper respiratory infection, or use in combination with MIF to accurately diagnose the infection by C. pneumoniae. Material and method: Direct immunofluorescence (DIF) was developed to detect C. pneumoniae in nasopharyngeal specimens obtained from patients with upper respiratory tract infection, and normal individuals. IgM and IgG antibodies against C. pneumoniae by MIF were determined for evaluation of the detected C. pneumoniae and seroconversion. Results: DIF gave positive results in 29 of 37 (78.4%) samples from 31 patients. Fifteen samples positive by DIF illustrated antibody titers interpreted as acute C. pneumoniae infection, and eight DIF positive samples showed antibody titers of chronic infection. Negative results by both DIF and MIF were found in two patients and 23 of 25 by DIF but 20 of 25 by MIF in normal subjects. Five paired sera subsequently collected from three of the 31 patients illustrated seroconversion 2-4 months after the primary specimen collection, which gave positive results by DIF but negative for antibodies. Significant association was found between C. pneumoniae detection by DIF and antibodies by MIF when analysis was done in the group of patients and normal subjects (p < 0.001; Pearson chi-square test). Conclusion: DIF could be an alternative assay for early diagnosis of C. pneumoniae infection, and may be used in combination with MIF for accurate diagnosis of acute C. pneumoniae infection.